Cardiovascular and oncological diseases: how to break the vicious circle?
https://doi.org/10.31146/1682-8658-ecg-205-9-196-200
Abstract
Mortality from cardiovascular and oncological diseases has remained at record highs for many years. Clinicians pay attention to the frequent combination of these two pathologies. Naturally, the question arises, what unites seemingly different diseases among themselves? Modern cancer therapy has allowed many people to achieve a cure or a stable remission, but at the same time led to the appearance of cardiac pathology. The relationship between the development of cardiotoxic events after antitumor therapy has been well studied, but undeservedly little time is allocated in real clinical practice to study vasculotoxicity in patients. This approach can be considered as the earliest predictor of damage to the microvasculature as a result of specific therapy. The analysis of groups of anticancer drugs that cause chronic heart failure and damage to the vascular endothelium to the greatest extent was carried out. The main approaches to risk stratification in cardio-oncological patients are considered. The principles used in the prevention and treatment of cardio- and vasculotoxicity have been studied.
About the Authors
I. A. Khakuasheva
Kabardino-Balkarian State University
Russian Federation
Russian Federation
Murat Anatolyevich Umetov
Kabardino-Balkarian State University
Russian Federation
Russian Federation
D. M. Khakulova
Kabardino-Balkarian State University
Russian Federation
Russian Federation
M. A. Kardanov
Kabardino-Balkarian State University
Russian Federation
Russian Federation
References
1. Mohamad O., Tabuchi T., Nitta Y., et al. Risk of Subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study. Lancet Oncology. 2019; 20: 674-685. doi: 10.1016/S1470-2045(18)30931-8
2. Bolotina L.V., Ovchinnikov A. G. Problems of cardiovascular complications induced by chemotherapy and targeted drugs. Research’n Practical Medicine Journal. 2015;4:106-114.(in Russ.) doi: 10.17709/2409-2231-2015-2-77 @@Болотина Л. В., Овчинников А. Г. Проблемы сердечно-сосудистых осложнений, индуцированных химиотерапией и таргетными препаратами. Исследования и практика в медицине. 2015; 2(4): 106-114. doi: 10.17709/2409-2231-2015-2-77
3. Siegel R.L., Miller K. D., Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. doi:10.3322/caac.21551
4. Sturgeon K.M., Deng L., Bluethmann S. M., et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019; 40(48):3889-3897. doi:10.1093/eurheartj/ehz766
5. Bertero E., Robusto F., Rulli E., et al. Cancer Incidence and Mortality According to Pre-Existing Heart Failure in a Community-Based Cohort. J Am Coll Cardiol CardioOnc. 2022; 4(1):98-109. doi.org/10.1016/j.jaccao.2021.11.0076
6. De Boer R. A., Aboumsallem J. P., Bracun V., et al. A new classification of cardio-oncology syndromes. Cardiooncology. 2021;7(1):24. doi:10.1186/s40959-021-00110-1
7. Koene, R.J., Prizment A. E., Blaes A., et.al. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104-1114. doi:10.1161/CIRCULATIONAHA.115.020406
8. Jørgensen T.L., Hallas J., Friis S., et al.Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer. 2012;106(7):1353-1360. doi:10.1038/bjc.2012.46
9. Hutchins K.K., Siddeek H., Franco V. I., et al. Prevention of cardiotoxicity among survivors of childhood cancer. Br J Clin Pharmacol. 2017;83(3):455-465. doi:10.1111/bcp.13120
10. Chang H.M., Yeh E. Potential of Oncocardiology-Reply. JAMA Cardiol. 2017;2(7):818. doi:10.1001/jamacardio.2017.012211
11. Armenian S.H, Xu L., Ky B., Sun C., et.al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016;34(10):1122-30. doi: 10.1200/JCO.2015.64.0409
12. Тocchetti C.G, Ameri P., de Boer R. A., et al. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovasc Res. 2020;116:1820-1834. doi: 10.1093/cvr/cvaa222
13. Galán-Arriola C., Vílchez-Tschischke J.P., Lobo M., et.al. Coronary microcirculation damage in anthracycline cardiotoxicity. Cardiovasc Res. 2022;118(2):531-541. doi: 10.1093/cvr/cvab053
14. López-Sendón J., Álvarez-Ortega C., Zamora Auñon P., et.al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720-1729. doi: 10.1093/eurheartj/ehaa006
15. Lancellotti P., Suter T.M, López-Fernández T., et.al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J. 2019 40(22):1756-1763. doi: 10.1093/eurheartj/ehy453
16. Campia U., Moslehi J.J, Amiri-Kordestani L., et al. Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. Circulation.2019;139(15):838-839.
17. Čelutkienė J., Pudil R., López-Fernández T., et.al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). European journal of heart failure. 22(9):1504-1524. doi.org/10.1002/ejhf.1957
18. Garcia-Pavia P., Kim, Y., Restrepo-Cordoba M. A., Lunde, I. G., et.al. Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. Circulation. 2019:140(1):31-41. doi.org/10.1161/CIRCULATIONAHA.118.037934
19. Lyon A.R, Dent S., Stanway S., et.al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945-1960. doi: 10.1002/ejhf.1920
20. Korzeniowska K., Cieślewicz A., Chmara E., et.al. Photosensitivity reactions in the elderly population: questionnaire-based survey and literature review. Ther Clin Risk Manag. 2019;15:1111-1119. doi: 10.2147/TCRM.S215308
21. Cardinale D., Colombo A., Bacchiani G., et.al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981-1988. doi: 10.1161/CIRCULATIONAHA.114.013777
22. Sabatino J., De Rosa S., Tammè L., et al. Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc Diabetol. 2020;19(1):66. doi:10.1186/s12933-020-01040-5
23. Maia T.N., Araujo G. B., Teixeira J. A., et al. Cardiotoxicity of Doxorubicin Treatment and Physical Activity: A Systematic Review.Int J Cardiovasc Sci. 2017;30(1):70-80. doi: 10.5935/2359-4802.20170004
24. Fischetti F., Greco G., Cataldi S., et al. Effects of Physical Exercise Intervention on Psychological and Physical Fitness in Lymphoma Patients. Medicina. 2019; 55(7):379. doi: 10.3390/medicina5507037
25. Lenneman A.J., Wang L., Wigger M., et al. Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy. Am J Cardiol. 2013; 111(4):609-12. doi:10.1016/j.amjcard.2012.10.048
26. Armanios M. Telomeres and age-related disease: how telomere biology in forms clinical paradigms. The Journal of Clinical Investigation. 2013;123(3):996-1002. doi:10.1172/JCI66370
27. Yeh J.K., Lin M. H., Wang C. Y. Telomeres as Therapeutic Targets in Heart Disease. JACC Basic Transl Sci. 2019;4(7):855-865. doi: 10.1016/j.jacbts.2019.05.009. PMID: 31998853; PMCID: PMC6978555.
28. Duggan C., Risques R., Alfano C., et al. Change in peripheral blood leukocyte telomere length and mortality in breast cancer survivors. J Natl Cancer Inst. 2014;106(4). doi:10.1093/jnci/dju035
29. Sanoff H.K., Deal A. M., Krishnamurthy J., et al. Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst. 2014;106(4). doi:10.1093/jnci/dju057
30. Chatterjee S. Telomeres in health and disease. J Oral Maxillofac Pathol. 2017;21(1):87-91. doi:10.4103/jomfp.JOMFP_39_16
Review
For citations:
Khakuasheva I.A., Umetov M.A., Khakulova D.M., Kardanov M.A. Cardiovascular and oncological diseases: how to break the vicious circle? Experimental and Clinical Gastroenterology. 2022;(9):196-200. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-205-9-196-200
Views:
334
Email this article 